- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05898165
Inovações Futuras na Nova Detecção de Fibrilação Atrial (FIND-AF): Estudo Piloto (FIND-AF)
Inovações futuras na nova detecção de fibrilação atrial (FIND-AF): estudo piloto de uma pontuação de risco para detecção precoce de fibrilação atrial
The purpose of this study is to trial a new intervention - risk-guided AF screening using an EHR-based risk score and remote ECG monitoring process - and to characterise individuals at elevated predicted AF risk.
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
This pilot study will use a post-market device within its intended purpose and involve a change in standard care - that is the offer of ECG monitoring for individuals at risk of AF to understand whether this leads to an increase in detection rates of AF, and follow-through prescription of oral anticoagulation.
Starting with the population that are eligible for oral anticoagulation (men with a CHA2DS2VASC ≥ 2 and women with a CHA2DS2VASC ≥ 3), but without AF, this pilot study will use FIND-AF within its intended purpose to predict the absolute risk of AF diagnosis for individuals within the next 6 months. It will be observed whether systematic AF screening leads to higher detection rates of AF in individuals at higher risk for AF than individuals at lower risk for AF.
This will give pilot data for whether systematic screening for AF in individuals at higher AF risk results in an incrementally higher yield of AF detection compared with screening approaches that have been targeted by age and risk of AF-related stroke. If the pilot shows that detection rates for AF are higher in the group at higher AF risk, then it would be suitable to plan a randomised controlled trial to determine whether systematic AF screening guided by AF risk increases detection rates of AF compared with routine care, and whether this is associated with a lower rate of stroke. The detection rates during systematic AF screening in this pilot study for individuals at higher and lower risk can establish power calculations required for a full-scale study and whether the numeric score at which a clinician would implement the intervention can be optimised.
In addition, this pilot study will establish the technical, logistic and administrative feasibility of a full-scale remote AF screening study including issues of recruitment and protocol adherence. It will also inform as to whether individuals diagnosed with AF by systematic AF screening in the community will receive oral anticoagulation interventions in primary care, and thus whether treatment of screen-detected AF in a full-scale study should be implemented in primary care or in secondary care under cardiology.
Finally this study will offer participants at higher AF risk the opportunity to attend a research clinic to determine whether these individuals have risk factors and comorbidities that could be identified and treated to reduce their subsequent risk of AF and other adverse events. This will establish whether individuals at risk of AF will attend for review, and their burden of modifiable risk factors for AF. This will establish power calculations that would be required for a full-scale study to test the hypothesis that primary prevention of AF is possible through interventions aimed at individuals at risk of AF.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Locais de estudo
-
-
West Yorkshire
-
Leeds, West Yorkshire, Reino Unido, LS2 9JT
- University of Leeds
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Patients aged >30 will be invited to screening in primary care from information present in their electronic health record (EHR) and their FIND-AF score. They will be given Zenicor ECG devices for up to period of 3 week during which they will be asked to record 4 daily ECG recordings.
Those patients who are higher risk for AF based on their FIND-AF score, will be reviewed further for multi-modal phenotyping.
Patient with new AF detected will be managed by their primary care clinicians.
Descrição
Inclusion Criteria:
- Age at enrolment ≥30 years
- Men with CHA2DS2VASC ≥ 2 and women with a CHA2DS2VASC ≥ 3
Exclusion Criteria:
- Known diagnosis of AF
- On anticoagulation therapy
- On the palliative care register
- Unable to give written informed consent for participation in the study
- Unable to adhere to the study requirements
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
To determine whether detection rates of AF during ECG monitoring are higher amongst participants identified as higher risk of AF, compared with those identified as lower risk
Prazo: 6 months
|
Rate ratio of AF detection rates during ECG monitoring in participants identified as higher risk by FIND-AF compared with participants identified as lower risk |
6 months
|
|
To determine whether detection rates of AF during ECG monitoring are higher amongst participants identified as higher risk of AF, compared with those identified as lower risk
Prazo: 5 years
|
Rate ratio of AF detection rates during ECG monitoring in participants identified as higher risk by FIND-AF compared with participants identified as lower risk |
5 years
|
|
To determine whether detection rates of AF during ECG monitoring are higher amongst participants identified as higher risk of AF, compared with those identified as lower risk
Prazo: 10 years
|
Rate ratio of AF detection rates during ECG monitoring in participants identified as higher risk by FIND-AF compared with participants identified as lower risk |
10 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
To determine, of participants who are detected as having AF during ECG monitoring, the proportion who subsequently receive oral anticoagulation prescription
Prazo: 6 months
|
Number (%) of participants who receive an oral anticoagulant prescription after diagnoses of AF during ECG monitoring diagnosed |
6 months
|
|
To determine, of participants who are detected as having AF during ECG monitoring, the proportion who subsequently receive oral anticoagulation prescription
Prazo: 5 years
|
Number (%) of participants who receive an oral anticoagulant prescription after diagnoses of AF during ECG monitoring diagnosed |
5 years
|
|
To determine, of participants who are detected as having AF during ECG monitoring, the proportion who subsequently receive oral anticoagulation prescription
Prazo: 10 years
|
Number (%) of participants who receive an oral anticoagulant prescription after diagnoses of AF during ECG monitoring diagnosed |
10 years
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
To determine the AF detection rates amongst participants who are identified as higher risk and lower risk, including in the periods outside of ECG monitoring to determine the incremental yield that is achieved by ECG monitoring over routine care
Prazo: 6 months
|
Risk of recorded AF diagnosis in EHR between individuals identified at higher and lower risk at six months after enrolment |
6 months
|
|
To determine how diagnostic yield, C statistic/AUROC, NPV, PPV, sensitivity and specificity, varies at different cut off points of the FIND-AF risk score
Prazo: 6 months
|
Diagnostic yield, PPV, NPV, sensitivity and specificity amongst participants who receive ECG monitoring, to understand whether the numeric score at which a clinician implements ECG monitoring can be optimised |
6 months
|
|
To determine the C statistic/AUROC, NPV, PPV, sensitivity and specificity for alternative approaches to guide systematic AF screening in participants who receive ECG monitoring:
Prazo: 6 months
|
Diagnostic yield, C statistic/AUROC, PPV, NPV, sensitivity and specificity in patients who are : CHA2DS2VASC≥3 in men and CHA2DS2VASC≥4 in women, age ≥70 years and age 75 and 76 years |
6 months
|
|
To determine if yield from ECG monitoring varies across age groups (≥75 years and ≤75 years) and sex (men and women)
Prazo: 6 months
|
AF detection rates and risks comparing higher and lower risk participants stratified by subgroup |
6 months
|
|
To determine recruitment rates, overall study.
Prazo: Up to 24 months
|
Number (%) of people who consent to participate compared to number of people who are invited |
Up to 24 months
|
|
To determine withdrawal rates
Prazo: Up to 24 months
|
Number (%) of people who consent to participate but subsequently withdraw consent / decline ECG monitoring |
Up to 24 months
|
|
To determine if there are differences between those who participate and those that do not participate
Prazo: Up to 24 months
|
Characteristics of those who consent to participate and do not consent to participate |
Up to 24 months
|
|
To determine if there are differences between those who participate and those that withdraw
Prazo: Up to 24 months
|
Characteristics of those who participate and those that withdraw |
Up to 24 months
|
|
To determine the adherence of ECG recordings amongst participants
Prazo: Up to 24 months
|
Mean number of recordings compared to the maximum stipulated Number (%) of participants who record less than 50% of stipulated amount of ECG recordings |
Up to 24 months
|
|
To determine the number of ECG recordings that need to be reviewed for possible AF detection
Prazo: Up to 24 months
|
Number (%) of ECG recordings flagged as abnormal by the algorithm within ECG recorder software that require manual review to assess for potential AF diagnosis |
Up to 24 months
|
|
To determine the burden of other arrhythmias that are diagnosed through ECG monitoring in participants identified as higher risk and lower risk
Prazo: Up to 24 months
|
Number (%) of participants who are diagnosed with other arrhythmias ( (atrial tachycardia, supraventricular tachycardia, 2nd degree AV block, high grade AV block or 3rd degree heart block, pause/asystole, ventricular tachycardia, ventricular fibrillation) during ECG monitoring in participants |
Up to 24 months
|
|
To determine the burden of non-diagnostic rhythm reports from ECG monitoring
Prazo: Up to 24 months
|
Number (%) of participants who have an ECG monitoring period with consistent poor quality which precludes a diagnostic result |
Up to 24 months
|
|
To determine recruitment rates - research clinic appointment
Prazo: Up to 24 months
|
Number (%) of people who consent to attend a research clinic appointment compared to number of people who are invited |
Up to 24 months
|
|
To determine what other conditions and cardiovascular risk factors are identified amongst participants classified as higher risk for AF at research clinic
Prazo: End of recruitment
|
Descriptive statistics of demographics, morbidities, medications, and cardiac ultrasound findings |
End of recruitment
|
|
To observe the clinical outcomes of participants that participate in the study, and whether there is a difference between participants identified as higher and lower risk?
Prazo: 5 years from completion of recruitment
|
Number (%) of participants who experience at 5 years:
|
5 years from completion of recruitment
|
|
To observe the clinical outcomes of participants that participate in the study, and whether there is a difference between participants identified as higher and lower risk?
Prazo: 10 years from completion of recruitment
|
Number (%) of participants who experience at 10 years:
|
10 years from completion of recruitment
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Chris Gale, Yes, University of Leeds
Publicações e links úteis
Publicações Gerais
- Hamilton E, Shone L, Reynolds C, Wu J, Nadarajah R, Gale C. Perceptions of healthcare professionals on the use of a risk prediction model to inform atrial fibrillation screening: qualitative interview study in English primary care. BMJ Open. 2025 Feb 5;15(2):e091675. doi: 10.1136/bmjopen-2024-091675.
- Nadarajah R, Wahab A, Reynolds C, Raveendra K, Askham D, Dawson R, Keene J, Shanghavi S, Lip GYH, Hogg D, Cowan C, Wu J, Gale CP. Future Innovations in Novel Detection for Atrial Fibrillation (FIND-AF): pilot study of an electronic health record machine learning algorithm-guided intervention to identify undiagnosed atrial fibrillation. Open Heart. 2023 Sep;10(2):e002447. doi: 10.1136/openhrt-2023-002447.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 318197_V1.0_230509
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
No individual participant data will be shared.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .